Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.

Radek LakomyAlexandr PoprachZbynek BortlicekBohuslav MelicharRenata ChloupkovaRostislav VyzulaMilada ZemanovaKaterina KopeckovaMarek SvobodaOndrej SlabyIgor KissHana StudentovaJaroslav JuracekOndrej FialaJindrich KopeckyJindrich FinekLadislav DusekKarel HejdukTomas Buchler

Published in: BMC cancer (2017)

In this retrospective study, no significant differences in survival were observed between the cohorts treated with different second-line agents including everolimus, sorafenib, and sunitinib.

Keyphrases

metastatic renal cell carcinoma
electronic health record
quality improvement
big data
free survival
machine learning
deep learning